Skip to main content

Table 5 Comparative analysis of AITL patients based on the remission status at the time of allo-HCT

From: Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis

 

CR1 (N = 33)

CR > 1 (N = 75)

PR (N = 90)

Refractory (N = 38)

Outcomes

N

Prob (95% CI)

N

Prob (95% CI)

N

Prob (95% CI)

N

Prob (95% CI)

NRM

33

 

75

 

90

 

38

 

1-year

 

6 (1–17)%

 

20 (12–30)%

 

20 (13–29)%

 

24 (12–38)%

2-year

 

13 (4–26)%

 

29 (19–40)%

 

25 (17–35)%

 

30 (16–45)%

3-year

 

17 (6–32)%

 

31 (21–43)%

 

25 (17–35)%

 

30 (16–45)%

4-year

 

17 (6–32)%

 

36 (25–49)%

 

33 (22–44)%

 

30 (16–45)%

Progression/ relapse

33

 

75

 

90

 

38

 

1-year

 

15 (5–29)%

 

13 (7–22)%

 

14 (7–21)%

 

29 (16–44)%

2-year

 

25 (12–41)%

 

16 (9–26)%

 

19 (11–28)%

 

29 (16–44)%

3-year

 

25 (12–41)%

 

18 (10–28)%

 

19 (11–28)%

 

32 (18–48)%

4-year

 

25 (12–41)%

 

18 (10–28)%

 

21 (12–30)%

 

32 (18–48)%

PFS

33

 

75

 

90

 

38

 

1-year

 

79 (63–91)%

 

67 (56–77)%

 

66 (56–76)%

 

47 (32–63)%

2-year

 

62 (45–78)%

 

54 (43–66)%

 

56 (45–66)%

 

41 (26–57)%

3-year

 

58 (41–75)%

 

50 (38–62)%

 

56 (45–66)%

 

38 (23–54)%

4-year

 

58 (41–75)%

 

45 (33–58)%

 

47 (36–58)%

 

38 (23–54)%

Overall survival

33

 

75

 

90

 

38

 

1-year

 

88 (75–97)%

 

73 (63–83)%

 

71 (61–80)%

 

63 (47–78)%

2-year

 

78 (62–90)%

 

62 (51–73)%

 

59 (48–69)%

 

52 (36–67)%

3-year

 

70 (52–85)%

 

58 (46–70)%

 

57 (47–68)%

 

52 (36–67)%

4-year

 

70 (52–85)%

 

54 (41–66)%

 

50 (39–62)%

 

52 (36–67)%

  1. CR complete response, PR partial response, Prob probability, CI confidence interval, N number, NRM non-relapse mortality, PFS progression-free survival